95 Results for "

ABCG

" in MedChemExpress (MCE) Product Catalog:
Products (95)

95 Results for "ABCG" in MCE Product Catalog:

  • Targets Recommended:
53
53 Publications Verification
Art. -Nr.: HY-10440
CAS. Nr.: 879085-55-9
Reinheit:  99.83%
Synonyms: GDC-0449
Vismodegib (GDC-0449) is a BBB-permeable and orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively .
49
49 Cited Publications
Art. -Nr.: HY-10010
CAS. Nr.: 461054-93-3
Reinheit:  99.97%
Target:  

BCRP

Forschungsgebiete:  

Cancer

Ko 143 is a potent and selective ATP-binding cassette subfamily G member 2 (ABCG2/BCRP) inhibitor. Ko 143 displays >200-fold selectivity over P-gp and MRP-1 transporters .
30
30 Cited Publications
Art. -Nr.: HY-101570
CAS. Nr.: 1637542-33-6
Reinheit:  99.70%
Synonyms: Peposertib; M3814
Target:  

DNA-PK BCRP

Forschungsgebiete:  

Cancer

Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .
13
13 Cited Publications
Art. -Nr.: HY-101561
CAS. Nr.: 1703793-34-3
Reinheit:  99.75%
Synonyms: BLU-285
Target:  

c-Kit PDGFR

Forschungsgebiete:  

Cancer

Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor with IC50s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Avapritinib (BLU-285) binds the active conformation of the kinase and shows antitumor activity. Avapritinib (BLU-285) attenuates the transport function of both ABCB1 and ABCG2 .
6
6 Cited Publications
Art. -Nr.: HY-10873
CAS. Nr.: 356068-97-8
Reinheit:  99.90%
Synonyms: SU-12662
Target:  

Drug Metabolite

Forschungsgebiete:  

Cancer

N-Desethyl Sunitinib (SU-12662) is a metabolite of Sunitinib (HY-10255A). N-Desethyl Sunitinib serves as a good transport substrate for human ABCB1, ABCG2 and murine ABCG2 .
3
3 Cited Publications
Art. -Nr.: HY-109061
CAS. Nr.: 1903008-80-9
Reinheit:  99.87%
Synonyms: YH25448; GNS-1480
Lazertinib (YH25448; GNS-1480) is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
3
3 Cited Publications
Art. -Nr.: HY-N2143
CAS. Nr.: 118974-02-0
Synonyms: 12α-Fumitremorgin C
Fumitremorgin C is a potent and selective ABCG2/BRCP inhibitor.
3
3 Cited Publications
Art. -Nr.: HY-11079
CAS. Nr.: 944261-79-4
Reinheit:  99.09%
A-803467 is a potent and selective tetrodotoxin-resistant Nav1.8 sodium channel blocker (IC50=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter .
3
3 Cited Publications
Art. -Nr.: HY-109061B
CAS. Nr.: 2247995-37-3
Synonyms: YH25448 mesylate; GNS-1480 mesylate
Forschungsgebiete:  

Cancer

Lazertinib (YH25448; GNS-1480) mesylate is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib mesylate exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib mesylate induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib mesylate competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib mesylate is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
3
3 Cited Publications
Art. -Nr.: HY-18010
CAS. Nr.: 330786-25-9
Target:  

Btk BCRP

Forschungsgebiete:  

Inflammation/Immunology

PCI 29732 is a potent, orally active, reversible BTK inhibitor with Ki app values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase. PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 .
2
2 Cited Publications
Art. -Nr.: HY-12757
CAS. Nr.: 912287-56-0
Reinheit:  99.65%
Target:  

BCRP

Forschungsgebiete:  

Cancer

YHO-13177, a acrylonitrile derivative, is an orally active, potent and specific inhibitor of breast cancer resistance protein (BCRP) and ABCG2 with an IC50 value of 10 nM. YHO-13177 potentiates the cytotoxicity of SN-38 in HCT116 and A549 cells that express BCRP. YHO-13177 combined with Irinotecan (HY-16562) significantly suppresses the tumor growth in an HCT116/BCRP xenograft model .
1
1 Cited Publications
Art. -Nr.: HY-100933
CAS. Nr.: 78351-75-4
Reinheit:  99.86%
MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, phosphodiesterase type 5 (PDE5), with a Ki of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter ABCG2, with anti-proliferative effect .
1
1 Cited Publications
Art. -Nr.: HY-P82096
Synonyms: ATP-binding cassette transporter 8; White protein homolog; ABC8; WHT1; ABCG1; ABC transporter 8; WHITE1

Host:  

Rabbit

Application:  

WB

Reactivity:  

Human

Art. -Nr.: HY-W020012
CAS. Nr.: 78949-95-8
Synonyms: 22-NBD Cholesterol
Target:  

Fluorescent Dye

Forschungsgebiete:  

Metabolic Disease

Fluoresterol (22-NBD Cholesterol) is a cholesterol-specific fluorescent probe with cholesterol-mimicking binding properties. Fluoresterol is ineffective orally and does not cross the blood-brain barrier. Fluoresterol specifically binds to cholesterol transport-related proteins (such as ABCA1 and ABCG1) and is primarily used in cholesterol metabolism research, particularly for the visualization and quantitative analysis of cholesterol absorption, efflux, intracellular transport efficiency, and reverse cholesterol transport (RCT) processes. The commonly used concentration of Fluoresterol in in vitro experiments is 0.1-10 μM, and the commonly used dose in in vivo experiments is 5-20 mg/kg (gavage or intraperitoneal injection), with excitation/emission wavelengths of 472/540 nm. Fluoresterol can be applied to the study of cholesterol metabolism mechanisms related to hyperlipidemia, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD) .
Art. -Nr.: HY-12758
CAS. Nr.: 1346753-00-1
Reinheit:  99.16%
Target:  

BCRP

Forschungsgebiete:  

Cancer

YHO-13351 is an orally active ABCG2 inhibitor . YHO-13351 modulates the function of ABCG2, blocks BCRP-mediated compound efflux, downregulates the expression of breast cancer resistance protein at the post-transcriptional level, and reverses ABCG2-associated tolerance. YHO-13351 restores the toxicity of SN-38 to SN-38-resistant cancer cells and sensitizes cancer cells to Irinotecan. YHO-13351 is a water-soluble prodrug that is rapidly converted to YHO-13177 (HY-12757) in mice. YHO-13351 prolongs the median survival time of mice bearing cancer cell xenografts when combined with IMMU-132. YHO-13351 extends the survival time of tumor-bearing mice and inhibits the growth of xenograft tumors when combined with Irinotecan. YHO-13351 can be used for the research of breast cancer, gastric cancer, BCRP-mediated drug-resistant cancers, and cervical cancer .
Art. -Nr.: HY-18282
CAS. Nr.: 898800-26-5
Target:  

LXR

AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis .
Art. -Nr.: HY-123148
CAS. Nr.: 870768-70-0
Reinheit:  99.85%
Target:  

LXR

Forschungsgebiete:  

Inflammation/Immunology

IMB-808 is a potent LXRα/β dual agonist with EC50 values of 0.53 μM and 0.15 μM (0.15 μM, using GAL4-pGL4-luc reporter plasmid) for LXRβ and LXRα, respectively. IMB-808 promotes expression of genes related to reverse cholesterol transport (ABCA1 and ABCG1). IMB-808 can be used for the study of atherosclerosis research .
Art. -Nr.: HY-136450
CAS. Nr.: 100648-13-3
Reinheit:  98.78%
Synonyms: TCBZ-SO
Target:  

Parasite BCRP

Forschungsgebiete:  

Infection Cancer

Triclabendazole sulfoxide (TCBZ-SO) is an orally active ABCG2 inhibitor with antiparasitic activity. Triclabendazole sulfoxide inhibits ABCG2-mediated active efflux and ATPase activity. Triclabendazole sulfoxide increases the intracellular accumulation of Mitoxantrone (HY-13502). Triclabendazole sulfoxide reduces the apical-directed transepithelial transport of Nitrofurantoin and Danofloxacin, while increasing their basolateral-directed transepithelial transport. Triclabendazole sulfoxide elevates the plasma levels of sulfasalazine in wild-type mice. Triclabendazole sulfoxide decreases ABCG2-mediated secretion of Nitrofurantoin into milk in wild-type lactating mice. Triclabendazole sulfoxide can be used in the research of insecticidal agents and cancers such as breast cancer .
Art. -Nr.: HY-P5391
CAS. Nr.: 717919-61-4
Target:  

Bacterial

Forschungsgebiete:  

Others

LL-37(17-32) is a biological active peptide. (This peptide is an active segment of LL-37, a peptide derived from the C-terminal domain of human cathelicidin antimicrobial peptide. It has been reported that the LL17-32 peptide exhibits reversal effect on ABCG2-mediated multidrug resistance in cancer cell lines.)
Art. -Nr.: HY-N9516
CAS. Nr.: 517-37-3
Synonyms: TDHC
Category:  

Animals Steroids

Target:  

Endogenous Metabolite

Taurodehydrocholic acid is a biliary cholesterol secretion activator. Taurodehydrocholic acid significantly increases the expression of Abcg5 and decreases the expression of abc8. Taurodehydrocholic acid can be used in the study of cholesterol metabolism .